Ghent, October 24, 2024 – During the COVID pandemic, many of us have received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center for Inflammation Research, Ghent University, and University Hospital Ghent, among others, has found that such repeated vaccinations lead to the presence of mucosal antibodies, for example, inside the nose. Their work appears in Science Translational Medicine.
Protective booster shots
Part of the global response strategy against the COVID pandemic involves the administration of booster shots, or ‘vaccine updates’ to ensure protection against new variants of the SARS-CoV-2 virus.
The researchers set out to investigate the effects of multiple mRNA vaccines on mucosal immunity, referring to mucous membranes such as the ones on the inside of our noses. Specifically, the research involved a cohort of 183 participants who were sampled at multiple time points after primary and booster vaccinations.
PhD student Jozefien Declercq (VIB-UGent) explains: “We found that individuals who received multiple doses of mRNA vaccines exhibited a marked increase in neutralizing antibodies in nasal secretions, which are essential for blocking viral entry. Not only that, but the immune responses generated by mRNA vaccines may persist longer than previously thought, which provides hope for sustained protection against emerging variants of the virus.”
From the blood to the nose
How do the antibodies produced in response to the vaccine get to the nose, though?
Prof. Dr. Stijn Vanhee (VIB-UGent), co-senior author of the study, explains. “Using a mouse model, we discovered that most mucosal neutralizing antibodies were of systemic origin, with antibodies circulating in the blood migrating to the respiratory mucosa in the nose, suggesting that repeated vaccination stimulates systemic antibody production that can reach mucosal membranes.”
The findings suggest that repeated vaccinations not only bolster systemic immunity but also enhance mucosal antibody responses, providing a more robust defense against the virus.
Prof. Dr. Linos Vandekerckhove (Ghent University), co-senior author of the study, emphasizes the critical role of mucosal immunity in the fight against COVID-19. "Our study provides compelling evidence that repeated mRNA vaccinations can improve mucosal antibody responses, or stimulate pre-existing infection induced mucosal responses, which are vital for preventing infection at the entry points of the virus. This could have profound implications for public health strategies moving forward, especially as we face new variants of concern.”
Journal
Science Translational Medicine
Method of Research
Observational study
Subject of Research
People
Article Title
Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa
Article Publication Date
23-Oct-2024
COI Statement
BNL received consulting fees from Sanofi and GSK and holds stock options from ArgenX. PG has served as an advisor or speaker or has received research support from 3NT, Ablynx, ALK, ArgenX, AstraZeneca, Bekaert Textiles, Genentech, GSK, Hall Allergy, Medtronic, Novartis, Regeneron, Roche, Sanofi-Genzyme, Stallergenes-Greer, Teva, and Thermo Fisher. LV received grants from Gilead Sciences. XS is a scientific co-founder of Exevir Bio. The other authors declare that they have no competing interests.